GlassScriptPhysician profile
Sarah M Covington
NPI 1679937403
$4,554.52
in general payments reported to CMS, 2019-2025
41 companies · $1,881 in 2025
The $1,881 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $456 · 2024: $2,218 · 2025: $1,881.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,392 · Education: $163.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,391.54 |
| Education | $162.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $505.25 | 2024-2025 | Reblozyl, Opdivo |
| Astrazeneca Pharmaceuticals LP | $494.71 | 2023-2025 | Enhertu, Imfinzi, Tagrisso |
| Janssen Biotech, INC. | $408.95 | 2023-2025 | Carvykti, Rybrevant, Erleada |
| Novartis Pharmaceuticals Corporation | $367.50 | 2023-2025 | |
| Pfizer INC. | $346.38 | 2023-2025 | |
| Daiichi Sankyo INC. | $281.22 | 2024-2025 | Enhertu |
| Pharmacosmos Therapeutics INC. | $198.18 | 2023-2025 | Monoferric |
| Eisai INC. | $171.56 | 2023-2024 | |
| Incyte Corporation | $159.30 | 2024-2025 | Jakafi, Niktimvo, Monjuvi |
| Merck Sharp & Dohme LLC | $151.22 | 2024-2025 | Keytruda, Lynparza, Welireg |
| Takeda Pharmaceuticals U.S.A., INC. | $127.16 | 2024-2025 | Fruzaqla, Iclusig |
| Array Biopharma INC | $106.63 | 2023-2025 | Braftovi, Mektovi, Lorbrena |
| Seagen INC. | $87.99 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $79.16 | 2024-2025 | Libtayo |
| Genentech USA, INC. | $78.77 | 2024-2025 | Polivy, Venclexta, Ocrevus |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aveo Pharmaceuticals, INC. | $75.26 | 2023-2024 | Fotivda |
| Lilly USA, LLC | $70.81 | 2023-2024 | Verzenio, Jaypirca, Retevmo |
| Genzyme Corporation | $69.97 | 2024-2025 | |
| Exelixis INC. | $67.73 | 2024-2025 | Cabometyx |
| Emd Serono, INC. | $61.11 | 2024-2025 | |
| Tempus Ai, INC | $58.73 | 2024-2025 | Xt Cdx |
| Gilead Sciences, INC. | $52.12 | 2024-2025 | Trodelvy |
| Pharmaessentia USA Corporation | $47.88 | 2024-2025 | Besremi |
| Bayer Healthcare Pharmaceuticals INC. | $46.73 | 2024 | |
| Sobi, INC | $42.59 | 2024-2025 | |
| Taiho Oncology, INC. | $41.49 | 2024-2025 | |
| Tersera Therapeutics LLC | $37.81 | 2024-2025 | Zoladex |
| Adc Therapeutics America, INC. | $37.75 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $34.51 | 2024 | Xarelto |
| Karyopharm Therapeutics INC. | $28.68 | 2025 | Xpovio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.83 | 2024 | |
| Celgene Corporation | $24.04 | 2024 | Reblozyl |
| Glaxosmithkline, LLC. | $23.92 | 2024 | Ojjaara |
| Deciphera Pharmaceuticals INC. | $22.52 | 2025 | Qinlock, Romvimza |
| Adaptive Biotechnologies Corporation | $21.35 | 2025 | Clonoseq |
| Geron Corporation | $19.79 | 2025 | Rytelo |
| Fennec Pharmaceuticals, INC. | $19.66 | 2024 | Pedmark |
| Abbvie INC. | $18.70 | 2025 | |
| Alexion Pharmaceuticals, INC. | $17.78 | 2025 | Ultomiris |
| Kyowa Kirin, INC. | $14.93 | 2023 | Poteligeo |
| Iovance Biotherapeutics, INC. | $7.85 | 2025 | Amtagvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Covington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.